Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Revenue: 2011-2025

Historic Revenue for Iovance Biotherapeutics (IOVA) over the last 4 years, with Sep 2025 value amounting to $67.5 million.

  • Iovance Biotherapeutics' Revenue rose 15.20% to $67.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $250.4 million, marking a year-over-year increase of 175.62%. This contributed to the annual value of $164.1 million for FY2024, which is 13698.99% up from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Revenue of $67.5 million as of Q3 2025, which was up 12.52% from $60.0 million recorded in Q2 2025.
  • Iovance Biotherapeutics' 5-year Revenue high stood at $73.7 million for Q4 2024, and its period low was $238,000 during Q2 2023.
  • Its 3-year average for Revenue is $34.2 million, with a median of $40.2 million in 2024.
  • Data for Iovance Biotherapeutics' Revenue shows a peak YoY skyrocketed of 15,189.21% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Iovance Biotherapeutics' Revenue stood at $482,000 in 2023, then soared by 15,189.21% to $73.7 million in 2024, then grew by 15.20% to $67.5 million in 2025.
  • Its Revenue stands at $67.5 million for Q3 2025, versus $60.0 million for Q2 2025 and $49.3 million for Q1 2025.